Trial Profile
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Autosomal dominant polycystic kidney disease; Hereditary nephritis; Renal failure
- Focus Adverse reactions; Registrational
- Acronyms EAGLE
- Sponsors Reata Pharmaceuticals
- 11 Aug 2023 This trial has been completed in Czechia as per European Clinical Trials Database record.
- 25 Jul 2023 This trial has been completed in Belgium (Date of the global end of the trial: 03-Jul-2023), according to the European Clinical Trials Database record.
- 12 Jul 2023 This trial has been completed in France (Date of the global end of the trial: 03-Jul-2023), according to the European Clinical Trials Database record.